Show simple item record

dc.contributor.authorGoodman, Alan G.
dc.contributor.authorHeinen, Paul P.
dc.contributor.authorGuerra, Susana M.
dc.contributor.authorVijayan, Aneesh
dc.contributor.authorSorzano, Carlos Oscar S.
dc.contributor.authorGómez, Carmen Elena
dc.contributor.authorEstéban, Mariano R.
dc.contributor.otherUAM. Departamento de Medicina Preventiva y Salud Pública y Microbiologíaes_ES
dc.date.accessioned2015-04-13T12:52:50Z
dc.date.available2015-04-13T12:52:50Z
dc.date.issued2011-10-05
dc.identifier.citationPlos One 6.10 (2011): e25938en_US
dc.identifier.issn1932-6203 (online)en_US
dc.identifier.urihttp://hdl.handle.net/10486/665056
dc.description.abstractThere is a need to develop a universal vaccine against influenza virus infection to avoid developing new formulations of a seasonal vaccine each year. Many of the vaccine strategies for a universal vaccine target strain-conserved influenza virus proteins, such as the matrix, polymerase, and nucleoproteins, rather than the surface hemagglutinin and neuraminidase proteins. In addition, non-disease-causing viral vectors are a popular choice as a delivery system for the influenza virus antigens. As a proof-of-concept, we have designed a novel influenza virus immunogen based on the NP backbone containing human T cell epitopes for M1, NS1, NP, PB1 and PA proteins (referred as NPmix) as well as a construct containing the conserved regions of influenza virus neuraminidase (N-terminal) and hemagglutinin (C-terminal) (referred as NA-HA). DNA vectors and vaccinia virus recombinants expressing NPmix (WR-NP) or both NPmix plus NA-HA (WR-flu) in the cytosol were tested in a heterologous DNA-prime/vaccinia virus-boost vaccine regimen in mice. We observed an increase in the number of influenza virus-specific IFNγ-secreting splenocytes, composed of populations marked by CD4 + and CD8 + T cells producing IFNγ or TNFα. Upon challenge with influenza virus, the vaccinated mice exhibited decreased viral load in the lungs and a delay in mortality. These findings suggest that DNA prime/poxvirus boost with human multi-epitope recombinant influenza virus proteins is a valid approach for a general T-cell vaccine to protect against influenza virus infectionen_US
dc.description.sponsorshipThis work was supported by Ministry of Science and Education of Spain Program JAE-DOC (CSIC-FSE) (to A.G.G), Spanish Ministry of Health Ramón y Cajal Program (FIS 2009-80145) (to S.G.), La Caixa Foundation International PhD Program Fellowship (to A.V.), and SAF-2008-02036 and the Marcelino Botín Foundation (to M.E.)en_US
dc.format.extent11 pag.es_ES
dc.format.mimetypeapplication/pdfen
dc.language.isoenges_ES
dc.publisherPublic Library of Scienceen_US
dc.relation.ispartofPlos Oneen_US
dc.rights© 2011 Goodman et al.es_ES
dc.subject.otherAmino Acid Sequenceen_US
dc.subject.otherInfluenza Vaccinesen_US
dc.subject.otherCD8-Positive T-Lymphocytesen_US
dc.subject.otherOrthomyxoviridaeen_US
dc.subject.otherCell Lineen_US
dc.titleA human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virusen_US
dc.typearticleen
dc.subject.ecienciaMedicinaes_ES
dc.identifier.doi10.1371/journal.pone.0025938es_ES
dc.identifier.publicationfirstpagee25938es_ES
dc.identifier.publicationissue10es_ES
dc.identifier.publicationlastpagee25938es_ES
dc.identifier.publicationvolume6es_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.rights.ccReconocimientoes_ES
dc.rights.accessRightsopenAccesses_ES
dc.facultadUAMFacultad de Medicina


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record